David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk.
David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech.
David Stermanon
Analyst Articles
What on Earth is Steven A. Cohen thinking? He’s authorized traders at his investment firm, SAC Capital, to quickly build a large position in Accretive Health (NYSE: AH). Roughly a week ago, SAC announced that it had already bought so many shares that it… Read More
The second quarter of 2012 has been a bummer so far, especially when you think back to what was a great first quarter in which the S&P 500 rose more than 12%. But I’m not discouraged. While the recovery may be proceeding at an excruciatingly slow pace, I still think… Read More
To Europe’s leaders and Greek voters, here’s a modest request: Will you please flip over all the cards and make the bold moves that markets are increasingly expecting? At this point, providing further bailout funds for Greece is simply foolish. No amount of money can turn this… Read More
Uber-investor Warren Buffett and I are quite different. Whereas Buffett typically looks for undervalued companies and buys them for the long haul, I usually like to buy stocks that are on a long-term uptrend that have a temporary pullback. And the quicker I can make a decent… Read More
Generic prescription drugs are the bane of big pharmaceutical companies and investors alike. As patents for name brand drugs expire, generics eat into revenue, shrink earnings, and depress stock prices of the Big Pharma players. But the smart investor knows that… Read More
In the past, I’ve told you where to find 57% of America’s best income stocks. For those who didn’t read that article, my research team found that 12 of the 21 best-performing American income stocks of the past decade came from a single sector — energy. (You… Read More
Over the past few years, I’ve been imploring investors to boost their exposure to the more dynamic economies and regions of the world. Simply put, Latin America, Asia and even Africa are poised to grow at a stronger pace in the next few decades than the United States and Europe. Read More
Every two weeks, we get a chance to look at fresh data on how heavily stocks are being shorted. It helps to see what short-sellers are focusing on — especially if you own one of the stocks being targeted. You’ll often see short positions in a particular… Read More
Although things are clearly looking up big-name domestic car companies such as Ford Motor Co. (NYSE: F) and General Motors (NYSE: GM), investors seeking an auto stock with eye-popping growth potential may want to look far away. Very far away, in fact — like about 8,000 miles. Read More
What the heck is going on with this market? On two occasions this week, the major indexes opened sharply lower and then clawed back higher as the trading session wore on. From hour to hour, the bears — who fear a spreading European contagion, and the… Read More